Evolving NSCLC Treatment Paradigm

Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.

FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.

The application is supported by the phase 3 SAFFRON trial, in which savolitinib plus osimertinib improved progression-free and overall survival vs chemotherapy.

US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.